- Home
- MQY vs FLGT Comparison
MQY vs FLGT Comparison
Compare MQY & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQY
- FLGT
- Stock Information
- Founded
- MQY 1994
- FLGT 2011
- Country
- MQY United States
- FLGT United States
- Employees
- MQY N/A
- FLGT N/A
- Industry
- MQY Investment Bankers/Brokers/Service
- FLGT Medical Specialities
- Sector
- MQY Finance
- FLGT Health Care
- Exchange
- MQY Nasdaq
- FLGT Nasdaq
- Market Cap
- MQY 846.2M
- FLGT 508.7M
- IPO Year
- MQY N/A
- FLGT 2016
- Fundamental
- Price
- MQY $11.72
- FLGT $16.98
- Analyst Decision
- MQY
- FLGT Hold
- Analyst Count
- MQY 0
- FLGT 1
- Target Price
- MQY N/A
- FLGT $16.00
- AVG Volume (30 Days)
- MQY 184.8K
- FLGT 439.7K
- Earning Date
- MQY 01-01-0001
- FLGT 05-02-2025
- Dividend Yield
- MQY 4.73%
- FLGT N/A
- EPS Growth
- MQY N/A
- FLGT N/A
- EPS
- MQY N/A
- FLGT N/A
- Revenue
- MQY N/A
- FLGT $283,470,000.00
- Revenue This Year
- MQY N/A
- FLGT $11.70
- Revenue Next Year
- MQY N/A
- FLGT $9.90
- P/E Ratio
- MQY N/A
- FLGT N/A
- Revenue Growth
- MQY N/A
- FLGT N/A
- 52 Week Low
- MQY $9.82
- FLGT $14.57
- 52 Week High
- MQY $12.52
- FLGT $25.11
- Technical
- Relative Strength Index (RSI)
- MQY 35.68
- FLGT 50.73
- Support Level
- MQY $11.96
- FLGT $16.66
- Resistance Level
- MQY $12.05
- FLGT $17.67
- Average True Range (ATR)
- MQY 0.12
- FLGT 1.12
- MACD
- MQY -0.03
- FLGT 0.16
- Stochastic Oscillator
- MQY 24.00
- FLGT 50.42
About MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.